Insider Transactions in Q2 2024 at Biocryst Pharmaceuticals Inc (BCRX)
Insider Transaction List (Q2 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 24
2024
|
Amy E Mc Kee Director |
SELL
Open market or private sale
|
Direct |
8,600
-23.61%
|
$51,600
$6.32 P/Share
|
|
Jun 17
2024
|
Machelle Sanders Director |
SELL
Open market or private sale
|
Direct |
4,689
-14.46%
|
$28,134
$6.0 P/Share
|
|
Jun 14
2024
|
Theresa Heggie Director |
SELL
Open market or private sale
|
Direct |
6,698
-11.25%
|
$40,188
$6.11 P/Share
|
|
Jun 12
2024
|
Amy E Mc Kee Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+15.77%
|
-
|
|
Jun 12
2024
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+8.37%
|
-
|
|
Jun 12
2024
|
Machelle Sanders Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+17.38%
|
-
|
|
Jun 12
2024
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+10.28%
|
-
|
|
Jun 12
2024
|
Nancy J Hutson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+6.79%
|
-
|
|
Jun 12
2024
|
Alan G Levin Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+11.64%
|
-
|
|
Jun 12
2024
|
Steve Aselage Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+8.86%
|
-
|
|
Jun 12
2024
|
Steven K Galson Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+15.77%
|
-
|
|
Jun 12
2024
|
George B Abercrombie Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,820
+15.77%
|
-
|
|
May 31
2024
|
Theresa Heggie Director |
BUY
Grant, award, or other acquisition
|
Direct |
870
+1.62%
|
$5,220
$6.46 P/Share
|
|
May 31
2024
|
Vincent Milano Director |
BUY
Grant, award, or other acquisition
|
Direct |
870
+1.27%
|
$5,220
$6.46 P/Share
|
|
May 30
2024
|
Alan G Levin Director |
BUY
Open market or private purchase
|
Direct |
7,861
+14.88%
|
$47,166
$6.36 P/Share
|
|
May 24
2024
|
Steve Aselage Director |
BUY
Open market or private purchase
|
Indirect |
2,500
+50.0%
|
$15,000
$6.4 P/Share
|
|
May 20
2024
|
Nancy J Hutson Director |
BUY
Open market or private purchase
|
Direct |
5,000
+5.45%
|
$30,000
$6.38 P/Share
|
|
May 20
2024
|
Vincent Milano Director |
BUY
Open market or private purchase
|
Direct |
15,000
+18.29%
|
$90,000
$6.25 P/Share
|
|
May 14
2024
|
Anthony Doyle Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
36,300
+11.98%
|
$181,500
$5.57 P/Share
|
|
May 14
2024
|
Helen M. Thackray Chief R&D Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+9.93%
|
$150,000
$5.86 P/Share
|
|
May 13
2024
|
Steven K Galson Director |
BUY
Open market or private purchase
|
Direct |
21,940
+29.85%
|
$109,700
$5.49 P/Share
|
|
May 13
2024
|
Alane P Barnes Chief Legal Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+1.64%
|
$25,000
$5.53 P/Share
|
|
May 13
2024
|
Charles K Gayer Chief Commercial Officer |
BUY
Open market or private purchase
|
Direct |
30,000
+8.89%
|
$150,000
$5.47 P/Share
|
|
May 13
2024
|
Jon P Stonehouse President & CEO |
BUY
Open market or private purchase
|
Direct |
30,000
+2.59%
|
$150,000
$5.55 P/Share
|